On 3 February, interim results of a Phase III trial of AstraZeneca / Oxford’s Covid-19 vaccine were released, confirming that the vaccine is safe and effective at preventing Covid-19, according to an AstraZeneca press release. The primary analysis of the vaccine is likely to put pressure on other companies to demonstrate reductions in Covid-19 transmission as soon as possible.
While the efficacy profile of Pfizer / BioNTech’s Covid-19 vaccine may be higher after the second dose, the AstraZeneca / Oxford vaccine also demonstrated a reduction in asymptomatic transmissions, and healthcare providers are likely to be swayed. Other vaccines may have even more potent reductions in transmission, but more time will be needed for them to demonstrate this effect. This delay will benefit AstraZeneca.
Go deeper with GlobalData
Until the data for other vaccines become available, the AstraZeneca / Oxford vaccine is likely to see increased global uptake due to its impressive efficacy in reducing severe disease, hospitalisation, and mortality, as well as reductions in transmission. This is especially supported by the vaccine’s low cost, which widens its scope.
GlobalData expects that the low cost of the AstraZeneca / Oxford vaccine, at $16 less per dose than the Pfizer / BioNtech vaccine, will allow it to be used in low-income countries where Covid-19 prevalence is high and access to expensive vaccines may be limited.
The AstraZeneca / Oxford vaccine is helping the world recover from the pandemic at a faster rate. As the vaccine uses a longer dose interval of 12 weeks, the increase in vaccine efficacy will allow for a higher proportion of individuals to be vaccinated and protected while waiting for their second dose. Its higher efficacy after just one dose also means a reduction in transmission among people who are waiting for the second dose of the vaccine.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Pfizer Inc
AstraZeneca Plc
BioNTech SE